专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2010066418A8 USE OF FLT3 LIGAND FOR STRENGTHENING IMMUNE RESPONSES IN RNA IMMUNIZATION 审中-公开
标题翻译：使用FLT3配体改善RNA免疫中的免疫反应
公开(公告)号：WO2010066418A8
公开(公告)日：2010-08-12
申请号：PCT/EP2009008811
申请日：2009-12-09
申请人： BIONTECH AG , UNIV MAINZ JOHANNES GUTENBERG , SAHIN UGUR , TUERECI OEZLEM , KREITER SEBASTIAN , SELMI ABDERRAOUF
发明人： SAHIN UGUR , TUERECI OEZLEM , KREITER SEBASTIAN , SELMI ABDERRAOUF
IPC分类号： A61K39/39 , C07K14/475
CPC分类号： A61K39/39 , A61K2039/53 , A61K2039/55516 , C07K14/475 , C07K2319/00
摘要： The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).
摘要翻译：本发明涉及将疫苗RNA递送至细胞。具体而言，本发明涉及疫苗RNA和Flt3配体在对动物（包括人类）施用时诱导，产生或增强免疫应答的共同使用。

2. 发明专利

CA2747180C USE OF FLT3 LIGAND FOR ENHANCING IMMUNE RESPONSES IN RNA IMMUNIZATION 未知
公开(公告)号：CA2747180C
公开(公告)日：2015-02-03
申请号：CA2747180
申请日：2009-12-09
申请人： UNIV MAINZ JOHANNES GUTENBERG , BIONTECH AG
发明人： SAHIN UGUR , TUERECI OEZLEM , KREITER SEBASTIAN , SELMI ABDERRAOUF
IPC分类号： A61K39/39 , C07K14/475
摘要： The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).

3. 发明专利

DE102008061522A1 Verwendung von Flt3-Ligand zur Verstärkung von Immunreaktionen bei RNA-Immunisierung 未知
公开(公告)号：DE102008061522A1
公开(公告)日：2010-06-17
申请号：DE102008061522
申请日：2008-12-10
申请人： BIONTECH AG , UNIV MAINZ JOHANNES GUTENBERG
发明人： SAHIN UGUR , TUERECI OEZLEM , KREITER SEBASTIAN , SELMI ABDERRAOUF
IPC分类号： C12N15/12 , A61K39/00 , C12N15/01
摘要： Die Erfindung betrifft ein Zuführen von Vakzine-RNA an Zellen. Insbesondere betrifft die Erfindung eine gemeinsame Verwendung von Vakzine-RNA und Flt3-Ligand zur Induktion, Erzeugung oder Verstärkung einer Immunreaktion bei einer Verabreichung an Tiere (einschließlich des Menschen).

4. 发明专利

CA2747180A1 USE OF FLT3 LIGAND FOR ENHANCING IMMUNE RESPONSES IN RNA IMMUNIZATION 未知
公开(公告)号：CA2747180A1
公开(公告)日：2010-06-17
申请号：CA2747180
申请日：2009-12-09
申请人： BIONTECH AG , UNIV MAINZ JOHANNES GUTENBERG
发明人： SAHIN UGUR , TUERECI OEZLEM , KREITER SEBASTIAN , SELMI ABDERRAOUF
IPC分类号： A61K39/39 , C07K14/475
摘要： The invention relates to supplying vaccine RNA to cells. The invention relates in particular to a common use of vaccine RNA and Flt3 ligand for inducing, creating or enhancing an immune response when administered to animals (including humans).

5. 发明专利

DE10347710A1 未知
公开(公告)号：DE10347710A1
公开(公告)日：2005-11-10
申请号：DE10347710
申请日：2003-10-14
申请人： UNIV MAINZ JOHANNES GUTENBERG
发明人： SAHIN UGUR , KREITER SEBASTIAN , TUERECI OEZLEM
IPC分类号： C07K14/47 , C07K14/74 , C07K19/00 , A61K39/39 , C07H21/00
摘要： The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

6. 发明专利

DE102005046490A1 New nucleic acid molecule comprising promoter, a transcriptable nucleic acid sequence, a first and second nucleic acid sequence for producing modified RNA with transcriptional stability and translational efficiency 未知
公开(公告)号：DE102005046490A1
公开(公告)日：2007-03-29
申请号：DE102005046490
申请日：2005-09-28
申请人： UNIV MAINZ JOHANNES GUTENBERG
发明人： SAHIN UGUR , HOLTKAMP SILKE , TUERECI OEZLEM , KREITER SEBASTIAN
IPC分类号： A61K48/00 , C07H21/00 , C12N9/00 , C12N15/00
摘要： Nucleic acid molecule comprising (in 5'-3' transcription direction) (a) a promoter; (b) a transcriptable nucleic acid sequence or a nucleic acid sequence for inserting in to a transcriptable nucleic acid sequence; (c1) a first nucleic acid sequence, which corresponds to the 3'-non-translated region of a gene or is derived from it; and (c2) a second nucleic acid sequence, which corresponds to the 3'-non-translated region of a gene or is derived from it, is new. Independent claims are included for: (1) a nucleic acid molecule comprising (in 5'-3' transcription direction) (a) a promoter; (b) a transcriptable nucleic acid sequence or a nucleic acid sequence for inserting in to a transcriptable nucleic acid sequence; and (c) a nucleic acid sequence with a transcription under control of (a), where the nucleic acid sequence codes for a nucleotide sequence of at least 20 sequentially arranged A-nucleotide in the transcript; (2) a nucleic acid molecule obtained after linearization; (3) a RNA obtained by transcription, preferably in vitro transcription, with the nucleic acid molecule under control of (a); (4) a method for in vitro transcription of a selected RNA molecule, in order to increase its stability and/or translation efficiency, comprising coupling of a first nucleic acid sequence (b1), which corresponds to the 3'- non translated region of a gene or is derived from it, at the 3'-end of the nucleic acid sequence (a), which is transcriptable into RNA molecule; coupling of a second nucleic acid sequence (b2), which corresponds to the 3'-non-translated region of a gene or is derived from it, at the 3'-end the first nucleic acid sequence (b1), and in vitro transcription of obtained nucleic acid; (5) a method for the translation of a selected RNA molecule, in order to increase the expression, comprising coupling of the first nucleic acid sequence (b1); coupling of the second nucleic acid sequence (b2), and translating the mRNA that is obtained through transcription of the obtained nucleic acid; (6) an in vitro transcription of a selected RNA molecule, in order to increase its stability and/or translation efficiency, comprising coupling of a nucleic acid sequence (b), which codes for a nucleotide sequence of at least 20 sequentially arranged A-nucleotides, at the 3'-end of a nucleic acid sequence (a), which is transcriptable in to RNA molecule, and in vitro transcription of the obtained nucleic acid; (7) a method for the translation of a selected mRNA molecule, in order to increase its expression, comprising coupling of a nucleic acid sequence, which codes for a nucleotide sequence of at least 20 sequential A-nucleotides, at the 3'-end of the nucleic acid sequence (a), and translating mRNA, which is available by transcription of the obtained nucleic acid; and (8) a RNA obtained by the in vitro transcription of a selected RNA molecule.

7. 发明专利

DE10347710B4 未知
公开(公告)号：DE10347710B4
公开(公告)日：2006-03-30
申请号：DE10347710
申请日：2003-10-14
申请人： UNIV MAINZ JOHANNES GUTENBERG
发明人： SAHIN UGUR , KREITER SEBASTIAN , TUERECI OEZLEM
IPC分类号： C07K19/00 , A61K39/39 , C07H21/00 , C07K14/47 , C07K14/74
摘要： The present invention relates to fusion molecules of antigens, the nucleic acids coding therefor and the use of such fusion molecules and nucleic acids. In particular, said invention relates to fusion molecules, comprising an antigen and the trans-membrane region and cytoplasmic region of a MHC molecule and/or the cytoplasmic region of a MHC or a SNARE molecule.

8. 发明专利

JP2012235786A Modification of rna, producing an increased transcript stability and translation efficiency 有权
标题翻译： RNA的修饰，产生增加的转录稳定性和翻译效率
公开(公告)号：JP2012235786A
公开(公告)日：2012-12-06
申请号：JP2012154852
申请日：2012-07-10
申请人： Biontech Ag , ビオエンテッヒ・アクチェンゲゼルシャフトBioNTech AG
发明人： SAHIN UGUR , HOLTKAMP SILKE , TUERECI OEZLEM , KREITER SEBASTIAN
IPC分类号： C12N15/09 , C12N5/10
CPC分类号： C12N15/68 , C12N15/67 , C12N15/85
摘要： PROBLEM TO BE SOLVED: To provide RNA which is applicable to immunotherapy of vaccine or the like based on RNA, and in which transcript stability and translation efficiency are improved, and to provide a means to obtain such RNA.SOLUTION: A nucleic acid molecule includes a promoter, a nucleic acid sequence that can be transcribed, and a consecutive A nucleotide sequence. The nucleic acid molecule includes a sequence which can be performed with in vitro transcription after being made to be a straight chain by restriction cleavage. A transcribed RNA is used to transfect a host cell. A transfected antigen-presenting cell is disclosed, especially a dendritic cells, monocyte or macrophage are disclosed.
摘要翻译：要解决的问题：提供适用于基于RNA的疫苗等的免疫治疗的RNA，并且其中转录物稳定性和翻译效率得到改善，并提供获得此类RNA的方法。解决方案：核酸分子包括启动子，可被转录的核酸序列和连续的A核苷酸序列。核酸分子包括可以通过限制性切割在被制成直链后通过体外转录进行的序列。转录的RNA用于转染宿主细胞。公开了转染的抗原呈递细胞，特别是公开了树突状细胞，单核细胞或巨噬细胞。版权所有（C）2013，JPO＆INPIT

9. 发明申请

WO2015043613A8 PARTICLES COMPRISING A SHELL WITH RNA 审中-公开
标题翻译：用RNA包裹壳的颗粒
公开(公告)号：WO2015043613A8
公开(公告)日：2015-05-21
申请号：PCT/EP2013002898
申请日：2013-09-26
申请人： BIONTECH AG , TRON TRANSLATIONALE ONKOLOGIE AN DER UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITÄT MAINZ GE , UNIVERSITÄTSMEDIZIN DER JOHANNES GUTENBERG UNIVERSITÄT MAINZ
发明人： SAHIN UGUR , HAAS HEINRICH , KREITER SEBASTIAN , HÜSEMANN YVES , DIKEN MUSTAFA , REUTER KERSTIN , HEFESHA HOSSAM
IPC分类号： A61K9/127 , A61K9/50 , A61K31/663 , A61K48/00
CPC分类号： A61K39/39 , A61K9/1271 , A61K9/1277 , A61K9/5073 , A61K31/675 , A61K39/0011 , A61K2039/55505 , A61K2039/55511 , A61K2039/55516 , A61K2039/55555 , A61K2039/55561 , A61K2039/572 , C12N15/88 , C12N2810/10
摘要： The present invention relates to RNA decorated particles such as RNA decorated lipid particles, preferably to RNA decorated liposomes. Further, the present invention relates to a pharmaceutical composition comprising RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes. Said pharmaceutical composition is useful for inducing an immune response. It is also useful in a prophylactic and/or therapeutic treatment of a disease involving an antigen. Furthermore, the present invention relates to a method for producing the RNA decorated particles such as RNA decorated lipid particles, preferably RNA decorated liposomes.
摘要翻译：本发明涉及RNA修饰的颗粒，例如RNA修饰的脂质颗粒，优选涉及RNA修饰的脂质体。此外，本发明涉及包含RNA修饰的颗粒如RNA修饰的脂质颗粒，优选RNA修饰的脂质体的药物组合物。所述药物组合物可用于诱导免疫应答。它也可用于预防和/或治疗涉及抗原的疾病。此外，本发明涉及用于生产RNA装饰颗粒的方法，例如RNA修饰的脂质颗粒，优选RNA修饰的脂质体。

10. 发明申请

WO2013143683A8 RNA FORMULATION FOR IMMUNOTHERAPY 审中-公开
标题翻译：用于免疫治疗的RNA制剂
公开(公告)号：WO2013143683A8
公开(公告)日：2013-12-12
申请号：PCT/EP2013000902
申请日：2013-03-25
申请人： BIONTECH AG , TRON TRANSLATIONALE ONKOLOGIE AN DER JOHANNES GUTENBERG UNI MAINZ GEMEINNUETZIGE GMBH , UNIVERSITAETSMEDIZIN DER JOHANNES GUTENBERG UNI MAINZ
发明人： SAHIN UGUR , HAAS HEINRICH , KREITER SEBASTIAN , DIKEN MUSTAFA , FRITZ DANIEL , MENG MARTIN , KRANZ LENA MAREEN , REUTER KERSTIN
IPC分类号： A61K9/127 , A61K39/00 , A61K48/00
CPC分类号： A61K48/0033 , A61K9/1272 , A61K39/0011 , A61K48/0025 , A61K2039/53 , A61K2039/55555
摘要： The present invention is in the field of immunotherapy, in particular tumor immunotherapy. The present invention provides pharmaceutical formulations for delivering RNA to antigen presenting cells such as dendrite cells (DCs) in the spleen after systemic administration. In particular, the formulations described herein enable to induce an immune response after systemic administration of antigen-coding RNA.
摘要翻译：本发明属于免疫治疗领域，特别是肿瘤免疫治疗领域。本发明提供了用于在全身施用后将RNA递送至脾中的抗原呈递细胞例如树突细胞（DC）的药物制剂。具体而言，本文描述的制剂能够在系统施用抗原编码RNA后诱导免疫应答。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式